6
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Risk to heroin users of poly-drug use of pregabalin or gabapentin

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          AIM

          To examine the risk to heroin users of also using gabapentin or pregabalin (gabapentoids).

          DESIGN

          Multidisciplinary study:- we (a) examined trends in drug related deaths and gabapentoid prescription data in England and Wales to test for evidence that any increase in deaths mentioning gabapentin or pregabalin is associated with trends in gabapentoid prescribing and is concomitant with opioid use; (b) interviewed people with a history of heroin use about their polydrug use involving gabapentin and pregabalin; (c) studied the respiratory depressant effects of pregabalin in the absence and presence of morphine in mice to determine whether concomitant exposure increased the degree of respiratory depression observed.

          SETTING

          England and Wales.

          PARTICIPANTS

          Interviews were conducted with 30 participants (19 males, 11 female).

          MEASUREMENTS

          (a) Office of National Statistics drug-related deaths from 1 January 2004 and 31 December 2015 that mention both an opioid and pregabalin or gabapentin; (b) subjective views on the availability, use, interactions, and effects of polydrug use involving pregabalin and gabapentin; (c) rate and depth of respiration.

          RESULTS

          Pregabalin and gabapentin prescriptions increased about 24% per year from 1 million in 2004 to 10.5 million in 2015. The number of deaths involving gabapentoids increased from less than one per year prior to 2009 to 137 in 2015; 79% of these deaths also involved opioids. The increase in deaths was highly correlated with the increase in prescribing (correlation coefficient 0.965; 5% increase in deaths per 100,000 increase in prescriptions). Heroin users described pregabalin as easy to obtain. They suggested that the combination of heroin and pregabalin reinforced the effects of heroin but were concerned it induced ‘black outs’ and increased the risk of overdose. In mice, a low dose of S-pregabalin (20 mg/kg) that did not itself depress respiration reversed tolerance to morphine depression of respiration (resulting in 35% depression of respiration, P<0.05) whereas a high dose of S-pregabalin (200 mg/kg) alone depressed respiration and this effect summated with that of morphine (producing over 50% depression of respiration, P<0.05).

          CONCLUSIONS

          For heroin users the combination of opioids with gabapentin or pregabalin potentially increases the risk of acute overdose death through either reversal of tolerance or an additive effect of the drugs to depress respiration.

          Related collections

          Most cited references18

          • Record: found
          • Abstract: found
          • Article: not found

          A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin.

          Pregabalin and gabapentin share a similar mechanism of action, inhibiting calcium influx and subsequent release of excitatory neurotransmitters; however, the compounds differ in their pharmacokinetic and pharmacodynamic characteristics. Gabapentin is absorbed slowly after oral administration, with maximum plasma concentrations attained within 3-4 hours. Orally administered gabapentin exhibits saturable absorption--a nonlinear (zero-order) process--making its pharmacokinetics less predictable. Plasma concentrations of gabapentin do not increase proportionally with increasing dose. In contrast, orally administered pregabalin is absorbed more rapidly, with maximum plasma concentrations attained within 1 hour. Absorption is linear (first order), with plasma concentrations increasing proportionately with increasing dose. The absolute bioavailability of gabapentin drops from 60% to 33% as the dosage increases from 900 to 3600 mg/day, while the absolute bioavailability of pregabalin remains at > or = 90% irrespective of the dosage. Both drugs can be given without regard to meals. Neither drug binds to plasma proteins. Neither drug is metabolized by nor inhibits hepatic enzymes that are responsible for the metabolism of other drugs. Both drugs are excreted renally, with elimination half-lives of approximately 6 hours. Pregabalin and gabapentin both show dose-response relationships in the treatment of postherpetic neuralgia and partial seizures. For neuropathic pain, a pregabalin dosage of 450 mg/day appears to reduce pain comparably to the predicted maximum effect of gabapentin. As an antiepileptic, pregabalin may be more effective than gabapentin, on the basis of the magnitude of the reduction in the seizure frequency. In conclusion, pregabalin appears to have some distinct pharmacokinetic advantages over gabapentin that may translate into an improved pharmacodynamic effect.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Abuse and Misuse of Pregabalin and Gabapentin

            Gabapentinoid (pregabalin and gabapentin) abuse is increasingly being reported.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Gabapentin misuse, abuse and diversion: a systematic review.

              Since its market release, gabapentin has been presumed to have no abuse potential and subsequently has been prescribed widely off-label, despite increasing reports of gabapentin misuse. This review estimates and describes the prevalence and effects of, motivations behind and risk factors for gabapentin misuse, abuse and diversion.
                Bookmark

                Author and article information

                Journal
                9304118
                2264
                Addiction
                Addiction
                Addiction (Abingdon, England)
                0965-2140
                1360-0443
                19 April 2017
                15 May 2017
                September 2017
                01 September 2018
                : 112
                : 9
                : 1580-1589
                Affiliations
                [1 ]School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol BS8 1TD, UK
                [2 ]School of Social and Community Medicine, University of Bristol, Bristol BS8 2PS, UK
                [3 ]Mortality Analysis, Office for National Statistics, Newport NP10 8XG, UK
                Author notes
                Corresponding Authors: Graeme Henderson, School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol BS8 1TD, UK, Graeme.henderson@ 123456bris.ac.uk , Tel: 44-117-9287629; Matthew Hickman, School of Social and Community Medicine, University of Bristol, Bristol BS8 2BN, UK, Matthew.Hickman@ 123456bristol.ac.uk , Tel: 44-117-3310016
                Article
                PMC5635829 PMC5635829 5635829 nihpa866501
                10.1111/add.13843
                5635829
                28493329
                a870d917-09ce-45ad-b095-971f75d4b331
                History
                Categories
                Article

                Comments

                Comment on this article